commercializes the product in the United States and Canada. Rapidscan Pharma Solutions, Inc. commercializes the product in Europe and select other markets.) Ranexa (ranolazine extended-release tablets) 500 mg and 1000 mg is indicated for the treatment of chronic angina. (First U.S. approval, ...
Gilead Sciences Canada, Inc. announced that Paul Petrelli joined the organization as Vice President and General Manager. In his new role, Petrelli will lead the commercial organization for Gilead Canada, focusing on expanding access to Gilead's therapies, driving sustainable growth...
The article informs that Gilead Sciences Inc. is planning to purchase a 10-acre plot in Edmonton, Alberta to build a research and development facility on the site.R.M.Chemical & Engineering News
Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV)...
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is ...
21Gilead Sciences GmbH子公司 22Gilead Apollo, LLC子公司 23Gilead Ireland Research UC子公司 24Gilead Sciences Malaysia Sdn. Bhd.子公司 25Gilead Sciences Canada, Inc.子公司 26Gilead Sciences Korea Limited子公司 27Gilead Calistoga, LLC子公司
Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for DESCOVY® (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for Pre-Exposure Prophylaxis (PrEP) to re...
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innov...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022. Chairman and Chief Executive Officer of Gilead Sciences, Daniel O’Day said: “This was another very strong quarter acro...
Gilead Sciences Inc. (GILD) $91.001.06(1.18%) Bid: 91.10 x 2600Ask: 91.29 x 2000 January 14, 2025 4:00 PMESTVolume: 7,418,301 After Hours: $91.450.45(0.49%)January 14, 2025 6:53 PMESTVolume: 486,961 USDNasdaq Global SelectDelayed PriceMarket Closed Earnings High Target Price 125.00...